Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...

Full description

Bibliographic Details

Published in:	Фармакоэкономика
Main Authors:	N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2019-01-01
Subjects:	prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation public spending
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/268